Cargando…

PB1962: COMPARISON OF EXPRESSION OF NSD2, CYCLIN D1 AND C-MAF BY PLASMA CELLS IN BONE MARROW AND BONE PLASMACYTOMA IN PATIENTS WITH PLASMA CELL MYELOMA

Detalles Bibliográficos
Autores principales:	Mamaeva, E., Firsova, M., Solovev, M., Abakumova, A., Startsev, A., Makunina, E., Kovrigina, A., Danilina, T., Mendeleeva, L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431755/ http://dx.doi.org/10.1097/01.HS9.0000850684.49920.ad

Ejemplares similares

PB1977: SPECTRUM OF INFECTIOUS COMPLICATIONS FOLLOWING TRANSPLANTATION OF AUTOLOGOUS BLOOD STEM CELLS IN PATIENTS WITH MULTIPLE MYELOMA
por: Abakumova, A., et al.
Publicado: (2022)

PB2031: CD269, CD319 EXPRESSION ON MALIGNANT PLASMA CELLS AND SOLUBLE BCMA, SLAMF7 PROTEINS COMPARATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
por: Startsev, A., et al.
Publicado: (2022)

PB2145: IMPACT OF A SIZE OF BONE PLASMACYTOMA ON THE COURSE OF MULTIPLE MYELOMA
por: Mamaeva, Elizaveta, et al.
Publicado: (2023)

Plasmacytoma in patients with multiple myeloma: morphology and immunohistochemistry
por: Firsova, Maiia V., et al.
Publicado: (2020)

PB1954: COMPARING STR PROFILES OF DNA ISOLATED FROM DIVERSE TUMOR SITES IN MULTIPLE MYELOMA
por: Firsova, M., et al.
Publicado: (2022)

Immunohistochemistry for identification of CCND1, NSD2, and MAF gene rearrangements in plasma cell myeloma
por: Murase, Takayuki, et al.
Publicado: (2019)

PB2077: COMPARISON OF PLASMA CELL PERCENTAGE BY BONE MARROW ASPIRATE MORPHOLOGY AND CD138-STAINED BONE MARROW BIOPSY IN SMOLDERING MYELOMA TO PREDICT TRANSFORMATION TO SYMPTOMATIC MYELOMA
por: Cashman, Helen, et al.
Publicado: (2023)

A Review for Solitary Plasmacytoma of Bone and Extramedullary Plasmacytoma
por: Kilciksiz, Sevil, et al.
Publicado: (2012)

Localised plasmacytomas in Taiwan: comparison between extramedullary plasmacytoma and solitary plasmacytoma of bone.
por: Shih, L. Y., et al.
Publicado: (1995)

PB2130: RATIONAL FOR METHOTREXATE USAGE FOR THE TREATMENT AND PREVENTION OF CNS INVOLVEMENT IN PATIENTS WITH HIGH-GRADE B-CELL LYMPHOMAS.
por: Misyurina, A., et al.
Publicado: (2022)

Osteoblastic Solitary Plasmacytoma of Bone
por: Sioka, Chrissa, et al.
Publicado: (2019)

Solitary Plasmacytoma of the Frontal Bone
por: Peker, Betul Cengız, et al.
Publicado: (2021)

PB2008: CUTANEOUS HEMORRHAGIC SYNDROME IN PATIENTS WITH AL-AMYLOIDOSIS
por: Khyshova, V., et al.
Publicado: (2022)

PB2327: BONE MARROW STUDY IN THROMBOPENIA
por: López De Ugarriza, P., et al.
Publicado: (2022)

PB2158: RELAPSING/REFRACTORY ABDOMINAL WALL EXTRA-MEDULLARY PLASMACYTOMAS DEMONSTRATING A RAPID COMPLETE RESPONSE TO BELANTAMAB MAFODOTIN
por: Ali, Mohamed, et al.
Publicado: (2023)

Analysis of the Biological Properties of Blood Plasma Protein with GcMAF Functional Activity
por: Dolgova, Evgeniya V., et al.
Publicado: (2022)

PB2244: FEATURES OF POLYCYTHEMIA VERA WITH THE JAK 2 EXON 12 MUTATION.
por: Soubortseva, Irina, et al.
Publicado: (2023)

Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis
por: Pavlovic, Milica, et al.
Publicado: (2015)

Soft Tissue Mass Extramedullary Plasmacytoma Following Radiation Therapy for Solitary Bone Plasmacytoma
por: Kim, Jong H, et al.
Publicado: (2023)

PB2282: MEK-KINASE INHIBITOR (TRAMETINIB) AS A TREATMENT OPTION FOR HAIRY CELL LEUKEMIA
por: Smirnova, Svetlana, et al.
Publicado: (2023)

A Patient with Synchronous Gallbladder and Bone Plasmacytoma
por: Markouli, Mariam, et al.
Publicado: (2023)

PB2202: FEATURES OF COLONY FORMING ABILITY OF BONE MARROW IN PATIENTS WITH NEUTROPENIA
por: Butolina, M., et al.
Publicado: (2022)

PB2344: STR-LOCI ALLELE IMBALANCE AT 9P24.1 AND PD-L1 EXPRESSION IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA.
por: Abdurashidova, Runiza, et al.
Publicado: (2023)

PB1962: INFLUENCE OF TRANSCRIPT TYPES IN SUSTAINED DEEP MOLECULAR RESPONSE (SDMR) AND TREATMENT-FREE REMISSION (TFR) IN CHRONIC PHASE-CHRONIC MYELOID LEUKEMIA (CP-CML) PATIENTS TREATED WITH TKI
por: Torra, Silvia Marce, et al.
Publicado: (2023)

Loss of Heterozygosity in the Circulating Tumor DNA and CD138+ Bone Marrow Cells in Multiple Myeloma
por: Soloveva, Maiia, et al.
Publicado: (2023)

PB2073: EVALUATION OF THE PLASMA METABOLOMIC PROFILE OF MGUS AND MULTIPLE MYELOMA PATIENTS
por: Ciesluk, Klaudia, et al.
Publicado: (2023)

PB2270: CLEARANCE OF PERSISTENT SARS-COV2 INFECTION WITH ANTIBODY CONTAINING PLASMA IN LEUKEMIA AND LYMPHOMA PATIENTS
por: Janssen, M., et al.
Publicado: (2022)

PB1937: UTILITY OF STERNAL BONE MARROW CELL MORPHOLOGY EVALUATION FOR DIAGNOSTIC CATEGORIZATION IN PATIENTS WITH ACQUIRED HYPOCELLULAR BONE MARROW FAILURE SYNDROMES
por: Chen, J., et al.
Publicado: (2022)

PB2342: A REVIEW OF BONE MARROW BIOPSIES PERFORMED AT A LONDON TEACHING HOSPITAL: DO BONE MARROWS AID DIAGNOSIS AND AT WHAT COST?
por: Mahbub, M., et al.
Publicado: (2022)

PB1868: COMPARISON OF MYELOBLAST CELL PERCENTAGE IN INVESTIGATIONS FOR ACUTE MYELOID LEUKAEMIA INCLUDING FLOW CYTOMETRY, BONE MARROW ASPIRATION AND BONE MARROW TREPHINE
por: Iftikhar, Naml
Publicado: (2023)

Solitary Bone Plasmacytoma of the Pelvis: A Rare Tumor
por: Karmali, Samir, et al.
Publicado: (2016)

Solitary plasmacytoma of the occipital bone: a case report
por: Wang, Lei, et al.
Publicado: (2020)

Recurrent solitary bone plasmacytoma: A case report
por: Sakhrekar, Rajendra, et al.
Publicado: (2021)

Bone Mineral Density After Transitioning From Denosumab to Alendronate
por: Kendler, David, et al.
Publicado: (2019)

In vitro histone lysine methylation by NSD1, NSD2/MMSET/WHSC1 and NSD3/WHSC1L
por: Morishita, Masayo, et al.
Publicado: (2014)

PB2338: BONE MARROW INVOLVEMENT IN KOREAN PATIENTS WITH LYMPHOMAS: A 21-YEAR LARGE SINGLE-CENTER STUDY: Keywords: Lymphoma, Bone marrow involvement
por: Kim, Min-Sun, et al.
Publicado: (2023)

PB1956: EVALUATION OF AN INNOVATIVE NEW METHOD FOR QUANTITATION OF PLASMA CELLS ON CD138 IMMUNOHISTOCHEMISTRY
por: Gantana, E., et al.
Publicado: (2022)

Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients
por: Ruberti, S, et al.
Publicado: (2018)

PB2302: HEPARIN-INDUCED THROMBOCYTOPENIA ANTIBODIES CAN MAINTAIN PLATELET-ACTIVATING PROPERTIES AFTER TWO SESSIONS OF THERAPEUTIC PLASMA EXCHANGE
por: Gkalea, V., et al.
Publicado: (2022)

EPO and hepcidin plasma concentrations in blood donors and β‐thalassemia intermedia are not related to commercially tested plasma ERFE concentrations
por: Schotten, Nienke, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_h4t8b4nd2nr8gc5qfa5og1u51o